Search bioRxiv⌕ Search

Biology subjects

Permentier, H.

Publications and source records attributed to Permentier, H..

3 recordsLinked to original sources

O-mannose glycosylations influence E-cadherin functional interactions

Cadherins are plasma membrane proteins that play critical roles in maintaining cell-cell adhesion and modulating cell signaling during development. Their functions are mediated by extracellular cadherin (EC) domains, which facilitate adhesive interactions and enable the formation of cis- and trans assemblies at adherens junctions and desmosomes. EC domains adopt a characteristic immunoglobulin-like fold composed of seven {beta}-strands (A-G) and are modified by N -linked and O -linked glycosylations, including O -linked mannose monosaccharides (O -Man) on conserved serine and threonine residues of B- and G-strands. O -Man glycosylations on EC domains are catalyzed by the TMTC1-4 enzymes, with different TMTC enzymes modifying B- or G-strands. Given the site-specific deposition of O -Man glycans by dedicated enzymes and the central role of EC domains in cadherins functions, we hypothesized that these PTMs may fine-tune cellular adhesion and otherwise contribute to diverse physical interactions that involve cadherins. To test these hypotheses, we assayed for changes in protein-protein interactions formed with epithelial (E)-cadherin in model cells where O -Man were genetically ablated. Herein, we report O -Man-dependent E-cadherin (CDH1) protein interactions, revealed by affinity proteomics, and we orthogonally validate an altered association between CDH1 and CDH3 (P-cadherin). We show different interactomic changes associated with O -Man ablation on B- vs. G-strands, highlighting the importance of these PTMs in CDH1-associated interaction. These findings provide new insights into how O -Man regulates CDH1-dependent protein complexes.

cell biology↗

pH-dependent spontaneous hydrolysis rather than gut bacterial metabolism reduces levels of the ADHD treatment, Methylphenidate

Methylphenidate is absorbed in the small intestine. The drug is known to have low bioavailability and a high interindividual variability in terms of response to the treatment. Gut microbiota has been shown to reduce the bioavailability of a wide variety of orally administered drugs. Here, we tested the ability of small intestinal bacteria to metabolize methylphenidate. In silico analysis identified several small intestinal bacteria to harbor homologues of the human carboxylesterase 1 enzyme responsible for the hydrolysis of methylphenidate in the liver. Despite our initial results hinting towards possible bacterial hydrolysis of the drug, up to 60% of methylphenidate was spontaneously hydrolyzed in the absence of bacteria and this hydrolysis was pH-dependent. Overall, the study shows that pH-dependent spontaneous hydrolysis rather than gut bacterial metabolism reduces levels of methylphenidate and suggest a role of the luminal pH in the bioavailability of the drug.View Full Text

microbiology↗

Bacterial deamination of residual levodopa medication for Parkinson's disease elicits inhibitory effect on gut motility

Aromatic bacterial metabolites are attracting considerable attention due to their impact on gut homeostasis and hosts physiology. Clostridium sporogenes is a key contributor to the production of these bioactive metabolites in the human gut. Here, we show that C. sporogenes deaminates levodopa, the main treatment in Parkinsons disease, and identify the aromatic aminotransferase responsible for the initiation of the deamination pathway. The deaminated metabolite from levodopa, 3-(3,4-dihydroxyphenyl)propionic acid, elicits an inhibitory effect on ileal motility in an ex vivo model. 3-(3,4-dihydroxyphenyl)propionic acid is detected in fecal samples of Parkinsons disease patients on levodopa medication. Our data are of significant impact to the treatment of Parkinsons disease, where constipation is reported as the most common gastrointestinal symptom. Overall, this study underpins the importance of the metabolic pathways of the gut microbiome involved in drug metabolism not only to preserve drug effectiveness, but also to avoid potential side effects of bacterial breakdown products of the unabsorbed residue of medication.

microbiology↗